Literature DB >> 17125911

KLF6 IVS1 -27G>A variant and the risk of prostate cancer in Finland.

Eija H Seppälä1, Ville Autio, Priya Duggal, Tarja Ikonen, Ulf-Håkan Stenman, Anssi Auvinen, Joan E Bailey-Wilson, Teuvo L J Tammela, Johanna Schleutker.   

Abstract

OBJECTIVES: A recent report demonstrated that KLF6 IVS1 -27G>A substitution increases the transcription of alternatively spliced isoforms; this action was suggested to be associated with prostate cancer (pCA). To evaluate these findings among the Finnish population, a total of 3348 samples were analysed.
METHODS: The variant was genotyped in 164 patients with familial pCA, 852 patients with unselected pCA, 459 patients with benign prostate hyperplasia (BPH), 923 male population controls, and 950 men from a Finnish prostate-specific antigen (PSA) screening trial with PSA levels less than 1.0ng/ml. Odds ratios (ORs) and corresponding 95% confidence intervals (95%CIs) were calculated by using logistic regression to estimate pCA risk.
RESULTS: Association testing revealed no significant differences between familial prostate cancer patients and population controls (OR: 0.84; 95%CI, 0.56-1.28; p=0.42), unselected cases and controls (OR: 0.95; 95%CI, 0.76-1.19; p=0.63), or BPH cases and controls (OR: 1.12; 95%CI, 0.86-1.46; p=0.39). pCA and BPH cases were also compared with PSA-screened controls. None of these analyses revealed any significant associations.
CONCLUSIONS: Our results do not support the suggested association of KLF6 IVS1 -27G>A germline polymorphism with pCA risk and also suggest that the variant is not a risk allele for BPH in the Finnish population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17125911     DOI: 10.1016/j.eururo.2006.11.019

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

1.  A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).

Authors:  Rong Na; Brian T Helfand; Haitao Chen; Carly A Conran; Susan E Crawford; Simon W Hayward; Teuvo L J Tammela; Judy Hoffman-Bolton; Siqun L Zheng; Patrick C Walsh; Johanna Schleutker; Elizabeth A Platz; William B Isaacs; Jianfeng Xu
Journal:  Prostate       Date:  2017-06-28       Impact factor: 4.104

2.  Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis.

Authors:  Christophe Bureau; Naima Hanoun; Jérôme Torrisani; Jean-Pierre Vinel; Louis Buscail; Pierre Cordelier
Journal:  Curr Genomics       Date:  2009-08       Impact factor: 2.236

3.  Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.

Authors:  Zsofia Kote-Jarai; Douglas F Easton; Janet L Stanford; Elaine A Ostrander; Johanna Schleutker; Sue A Ingles; Daniel Schaid; Stephen Thibodeau; Thilo Dörk; David Neal; Jenny Donovan; Freddie Hamdy; Angela Cox; Christiane Maier; Walter Vogel; Michelle Guy; Kenneth Muir; Artitaya Lophatananon; Mary-Anne Kedda; Amanda Spurdle; Suzanne Steginga; Esther M John; Graham Giles; John Hopper; Pierre O Chappuis; Pierre Hutter; William D Foulkes; Nancy Hamel; Claudia A Salinas; Joseph S Koopmeiners; Danielle M Karyadi; Bo Johanneson; Tiina Wahlfors; Teuvo L Tammela; Mariana C Stern; Roman Corral; Shannon K McDonnell; Peter Schürmann; Andreas Meyer; Rainer Kuefer; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Jo-Fen Liu; Tracy O'Mara; R A Frank Gardiner; Joanne Aitken; Amit D Joshi; Gianluca Severi; Dallas R English; Melissa Southey; Stephen M Edwards; Ali Amin Al Olama; Rosalind A Eeles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

Review 4.  Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy.

Authors:  Xiang Liu; Joseph C Cheng; Lorianne S Turner; Saeed Elojeimy; Thomas H Beckham; Alicja Bielawska; Thomas E Keane; Yusuf A Hannun; James S Norris
Journal:  Expert Opin Ther Targets       Date:  2009-12       Impact factor: 6.902

Review 5.  Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men.

Authors:  Rufus Cartwright; Altaf Mangera; Kari A O Tikkinen; Prabhakar Rajan; Jori Pesonen; Anna C Kirby; Ganesh Thiagamoorthy; Chris Ambrose; Juan Gonzalez-Maffe; Phillip R Bennett; Tom Palmer; Andrew Walley; Marjo-Riitta Järvelin; Vik Khullar; Chris Chapple
Journal:  Eur Urol       Date:  2014-01-22       Impact factor: 20.096

6.  Transcription factor KLF13 inhibits AKT activation and suppresses the growth of prostate carcinoma cells.

Authors:  Qiang Wang; Ruixian Peng; Boshi Wang; Jifeng Wang; Wandong Yu; Yongzhong Liu; Guowei Shi
Journal:  Cancer Biomark       Date:  2018       Impact factor: 4.388

7.  C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.

Authors:  C M Eklund; T L J Tammela; J Schleutker; M Hurme
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

Review 8.  Two Sides of the Same Coin: The Roles of KLF6 in Physiology and Pathophysiology.

Authors:  Saiful E Syafruddin; M Aiman Mohtar; Wan Fahmi Wan Mohamad Nazarie; Teck Yew Low
Journal:  Biomolecules       Date:  2020-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.